Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle

被引:135
作者
Ivanova, Gabriela D. [1 ]
Arzumanov, Andrey [1 ]
Abes, Rachida [2 ]
Yin, Haifang [3 ]
Wood, Matthew J. A. [3 ]
Lebleu, Bernard [2 ]
Gait, Michael J. [1 ]
机构
[1] MRC, Mol Biol Lab, Cambridge CB2 0QH, England
[2] Univ Montpellier 2, CNRS, UMR 5235, F-34095 Montpellier 5, France
[3] Univ Oxford, Dept Physiol Anat & Genet, Oxford OX1 3QX, England
基金
英国医学研究理事会;
关键词
D O I
10.1093/nar/gkn671
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Steric blocking peptide nucleic acid (PNA) oligonucleotides have been used increasingly for redirecting RNA splicing particularly in therapeutic applications such as Duchenne muscular dystrophy (DMD). Covalent attachment of a cell-penetrating peptide helps to improve cell delivery of PNA. We have used a HeLa pLuc705 cell splicing redirection assay to develop a series of PNA internalization peptides (Pip) conjugated to an 18-mer PNA705 model oligonucleotide with higher activity compared to a PNA705 conjugate with a leading cell-penetrating peptide being developed for therapeutic use, (R-Ahx-R)(4). We show that Pip-PNA705 conjugates are internalized in HeLa cells by an energy-dependent mechanism and that the predominant pathway of cell uptake of biologically active conjugate seems to be via clathrin-dependent endocytosis. In a mouse model of DMD, serum-stabilized Pip2a or Pip2b peptides conjugated to a 20-mer PNA (PNADMD) targeting the exon 23 mutation in the dystrophin gene showed strong exon-skipping activity in differentiated mdx mouse myotubes in culture in the absence of an added transfection agent at concentrations where naked PNADMD was inactive. Injection of Pip2a-PNADMD or Pip2b-PNADMD into the tibealis anterior muscles of mdx mice resulted in similar to 3-fold higher numbers of dystrophin-positive fibres compared to naked PNADMD or (R-Ahx-R)(4)-PNADMD.
引用
收藏
页码:6418 / 6428
页数:11
相关论文
共 45 条
[1]   Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy [J].
Aartsma-Rus, A ;
Bremmer-Bout, M ;
Janson, AAM ;
den Dunnen, JT ;
van Ommen, GJB ;
van Deutekom, JCT .
NEUROMUSCULAR DISORDERS, 2002, 12 :S71-S77
[2]   Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients [J].
Aartsma-Rus, A ;
Janson, AAM ;
Kaman, WE ;
Bremmer-Bout, M ;
den Dunnen, JT ;
Baas, F ;
van Ommen, GJB ;
van Deutekom, JCT .
HUMAN MOLECULAR GENETICS, 2003, 12 (08) :907-914
[3]   Antisense-mediated exon skipping: A versatile tool with therapeutic and research applications [J].
Aartsma-Rus, Annemieke ;
Van Ommen, Gert-Jan B. .
RNA, 2007, 13 (10) :1609-1624
[4]   Cell-penetrating-peptide-based delivery of oligonucleotides: an overview [J].
Abes, R. ;
Arzumanov, A. A. ;
Moulton, H. M. ;
Abes, S. ;
Lvanciva, G. D. ;
Lversen, P. L. ;
Gait, M. J. ;
Lebleu, B. .
BIOCHEMICAL SOCIETY TRANSACTIONS, 2007, 35 :775-779
[5]   Peptide-based delivery of nucleic acids: design, mechanism of uptake and applications to splice-correcting oligonucleotides [J].
Abes, S. ;
Moulton, H. ;
Turner, J. ;
Clair, P. ;
Richard, J. P. ;
Iversen, P. ;
Gait, M. J. ;
Lebleu, B. .
BIOCHEMICAL SOCIETY TRANSACTIONS, 2007, 35 :53-55
[6]   Endosome trapping limits the efficiency of splicing correction by PNA-oligolysine conjugates [J].
Abes, S ;
Williams, D ;
Prevot, P ;
Thierry, A ;
Gait, MJ ;
Lebleu, B .
JOURNAL OF CONTROLLED RELEASE, 2006, 110 (03) :595-604
[7]   Efficient splicing correction by PNA conjugation to an R6-Penetratin delivery peptide [J].
Abes, Said ;
Turner, John J. ;
Ivanova, Gabriela D. ;
Owen, David ;
Williams, Donna ;
Arzumanov, Andrey ;
Clair, Philippe ;
Gait, Michael J. ;
Lebleu, Bernard .
NUCLEIC ACIDS RESEARCH, 2007, 35 (13) :4495-4502
[8]   Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents [J].
Abes, Said ;
Moulton, Hong M. ;
Clair, Philippe ;
Prevot, Paul ;
Youngblood, Derek S. ;
Wu, Rebecca P. ;
Iversen, Patrick L. ;
Lebleu, Bernard .
JOURNAL OF CONTROLLED RELEASE, 2006, 116 (03) :304-313
[9]   Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology [J].
Alter, J ;
Lou, F ;
Rabinowitz, A ;
Yin, HF ;
Rosenfeld, J ;
Wilton, SD ;
Partridge, TA ;
Lu, QL .
NATURE MEDICINE, 2006, 12 (02) :175-177
[10]   Comparative analysis of antisense oligonucleotide sequences for targeted skipping of Exon 51 during dystrophin Pre-mRNA splicing in human muscle [J].
Arechavala-Gomeza, V. ;
Graham, I. R. ;
Popplewell, L. J. ;
Adams, A. M. ;
Aartsma-Rus, A. ;
Kinali, M. ;
Morgan, J. E. ;
Van Deutekom, J. C. ;
Wilton, S. D. ;
Dickson, G. ;
Muntoni, F. .
HUMAN GENE THERAPY, 2007, 18 (09) :798-810